Nasdaq:US$12.40 (-0.88) | HKEX:HK$21.60 (+1.00) | AIM:£2.16 (+0.05)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Careers
About Us
Overview
Corporate Information
Board of Directors
Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Careers
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
15 Nov 2022
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
Read more
14 Nov 2022
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
Read more
27 Oct 2022
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Read more
10 Oct 2022
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Read more
Scientific Publications
12 Sep 2022
ESMO2022: FRESCO-2: A global phase 3 multiregional clinical trial evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
Read more
6 Jun 2022
ASCO2022: Surufatinib in US Patients with Soft Tissue Sarcoma
Read more
6 Jun 2022
ASCO2022: A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs
Read more
12 Dec 2021
ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.